###### Strengths and limitations of this study

-   Study design---randomised, triple-blinded superiority trial.

-   Numerous clinically relevant secondary endpoints including gastro-oesophageal reflux disease, fatty liver disease, cardiovascular risk factors, bone metabolism and patient-reported outcome measures covering health-related quality of life, psychological distress, eating behaviour and gastrointestinal symptoms.

-   Predefined algorithms for optimising medications and supplementations related to primary and secondary outcomes.

-   Insulin secretion and action are calculated using both oral and intravenous glucose tolerance tests.

-   The sample size is limited and may, thus, not provide sufficient statistical power to detect clinically relevant differences in secondary outcomes.

Introduction {#s1}
============

Bariatric surgery is associated with long-term weight reduction and improvement of comorbidities, but also with adverse events and side effects.[@R1] Roux-en-Y gastric bypass was for many years considered the 'gold standard' of bariatric surgery, but recently sleeve gastrectomy, a technically easier and faster to perform procedure, has gained popularity and is now the most common bariatric procedure in the USA.[@R3]

For subjects with type 2 diabetes and obesity, bariatric surgery is a particularly effective treatment option, and a number of randomised trials have demonstrated the superiority of surgery over medical care for glycaemic control and remission of diabetes.[@R4] The improved glycaemic homoeostasis following bariatric surgery is to a large extent explained by the hypocaloric state and weight reduction. However, as improvements often are observed even before changes in body weight occur, some of the effects appear to be independent of weight loss and possibly related to the specific surgical procedure. Both gastric bypass and sleeve gastrectomy reduce the size of the stomach, but only gastric bypass includes a bypass of the duodenum and proximal small intestine. Thus, particularly, after gastric bypass, there is a rapid delivery of undigested food to the small intestine that enhances the release of gut-derived incretin hormones, such as glucagon-like peptide-1 (GLP-1), which further stimulate insulin secretion from pancreatic β-cells. Indeed, greater enhancement in postprandial GLP-1 levels have been observed after gastric bypass compared with sleeve gastrectomy,[@R10] while others have reported no significant differences.[@R11] The higher postprandial incretin hormone levels may be causally linked with the improved β-cell function observed after gastric bypass[@R14] and sleeve gastrectomy.[@R17] However, bariatric surgery is also accompanied by changes in other gut-derived and pancreatic-derived hormones, which directly or indirectly influence glycaemic control.[@R18]

A limited number of high-quality studies have compared the effect of gastric bypass and sleeve gastrectomy on remission of type 2 diabetes. Prior to the initiation of the present study, only one randomised controlled study had addressed glycaemic control in subjects with type 2 diabetes and obesity after gastric bypass and sleeve gastrectomy.[@R19] The STAMPEDE trial showed similar reduction in HbA1c 1 year after the two surgical procedures. In the following years, results from comparable randomised controlled trials have been published[@R20] including 3 and 5 years follow-up data from the STAMPEDE trial.[@R4] The remission rates of type 2 diabetes between the two procedures have not been statistically different in these trials. Thus, there is currently no conclusive evidence showing the superiority of gastric bypass or sleeve gastrectomy for patients with type 2 diabetes and obesity. Also, the impact of altered insulin secretion and action, gut microbiota, hepatic steatosis and gastric emptying on glycaemia after gastric bypass compared with sleeve gastrectomy is not clear. Additional relevant outcomes, including changes in body weight, obesity-related cardiovascular risk factors, symptoms and findings of gastro-oesophageal reflux disease, health-related quality of life, psychosocial status, eating behaviour, bone health, vitamin and mineral deficiencies, surgical complications and side effects, need further examination.

Objectives {#s1a}
----------

### Primary objectives {#s1a1}

The primary objectives of this study are to assess the effects of gastric bypass and sleeve gastrectomy on glycaemic control, diabetes remission and β-cell function.

### Secondary objectives {#s1a2}

Secondary objectives are to explore changes in variables that are related to the primary endpoints of the study (ie, body weight and composition, insulin sensitivity, liver fat content, energy intake, stomach emptying rate and intestinal microbiota). Moreover, we will explore cardiovascular risk factors influenced by weight reduction and possibly by changes in gut hormones (ie, blood pressure, arterial stiffness, albuminuria and lipids). Finally, we will examine possible differences in vitamin and mineral deficiencies, bone density, gastro-oesophageal reflux disease, hypoglycaemia, dumping syndrome, health-related quality of life, psychological distress, obesity-related symptoms, eating behaviour, nutrient intake, gastrointestinal symptoms and surgical and medical complications related to the two operations.

Trial design {#s1b}
------------

This study is a single-centre, triple-blinded, two-armed superiority trial randomising patients with type 2 diabetes and obesity in a 1:1 allocation ratio to either gastric bypass or sleeve gastrectomy.

Methods and analysis {#s2}
====================

Study setting {#s2a}
-------------

The study is carried out at the Morbid Obesity Centre at Vestfold Hospital Trust in Norway, a tertiary healthcare centre. The centre performs between 250 and 300 bariatric procedures (gastric bypass and sleeve gastrectomy) annually and about 25% of the patients have type 2 diabetes.[@R2] In 2012, when the Oseberg study was initiated, sleeve gastrectomy accounted for approximately 10% of bariatric procedures at our centre, increasing to approximately 40% in 2017.

Patient and public involvement {#s2b}
------------------------------

The steering committee includes a patient representative (MHK) to make sure that the patients' voices are heard. The burden of the interventions will be assessed using several patient-reported outcome measures questionnaires, regarding several aspects of health-related quality of life as well as gastrointestinal symptoms. The patients will receive summaries of published findings throughout the study period.

Inclusion and exclusion criteria {#s2c}
--------------------------------

### Inclusion criteria {#s2c1}

-   Previously verified body mass index (BMI)≥35.0 kg/m^2^ and current BMI≥33.0 kg/m^2^.

-   HbA1c≥6.5% or use of antidiabetic medications with HbA1c≥6.1%.

-   Age≥18 years.

### Exclusion criteria {#s2c2}

-   Not able to give informed consent.

-   Previously major abdominal surgery including bariatric surgery (appendectomy, laparoscopic cholecystectomy or gynaecological procedures not included).

-   Severe endocrine, heart, lung, liver and kidney disease, cancer and other medical conditions associated with significantly increased risk of perioperative and postoperative complications.

-   Drug or alcohol addiction.

-   Reduced compliance due to severe mental and psychiatric conditions.

-   Pregnancy.

-   Serum autoantibodies against glutamic acid decarboxylase (GAD) or tyrosine phosphatase (IA2).

-   Regular use (a total of 3 months cumulative use in the last 12 months) or treatment the past 2 months with systemic corticosteroids.

-   Severe gastro-oesophageal reflux disease defined as Los Angeles classification grade\>B, Barrett's oesophagus and/or hiatus hernia\>5 cm.

-   Elevated oesophageal pressure (DCI\>5000 mm Hg×s×cm) and symptoms of dysphagia and/or painful swallowing.

Interventions {#s2d}
-------------

All procedures were performed laparoscopically by experienced surgeons, and anaesthetists, familiar with obesity surgery, were responsible for the general anaesthesia. Anaesthesia was induced using propofol and rocuronium, while anaesthesia maintenance was achieved by combining desflurane gas and remifentanil infusion. Oral trimethoprim-sulpha was used as preoperative antibiotic prophylaxis.

The surgical procedures were standardised and similar in both gastric bypass and sleeve gastrectomy. Four trocars and one Nathanson's retractor were placed using identical skin incisions. Pneumoperitoneum was maintained at an intra-abdominal pressure of 15 mm Hg using CO~2~ insufflation. Dissection and haemostasis were conducted using ultrasonic shears (Harmonic Ace Ethicon EndoSurgery), and Sonicison, Medtronic (formerly Covidien) Echelon Flex (Ethicon EndoSurgery) or EndoGIA Ultra Universal Stapler (Covidien) was used for stapling. After reducing the intra-abdominal pressure to 10 mm Hg, all trocars were removed under visual guidance. Drains were not used.

### Roux-en-Y gastric bypass {#s2d1}

The left crus was dissected free and any hiatal hernia left in place. The minor curvature was opened at the second vessel and the lesser sac entered. A 25 mL gastric pouch was created by firing one horizontal and two vertical 45 mm blue (Ethicon) or tan (Medtronic, formerly Covidien) staple loads. The ligament of Treitz was identified and a proximal loop of small intestine anastomosed to the pouch 60 cm from the ligament of Treitz with one firing of a 45 mm linear stapler (white or tan load) using the full length of the stapler, creating an antecolic, antegastric alimentary limb. The opening was closed using a single row, running absorbable suture. An entero-enteroanastomosis was then made 120 cm distal of the gastro-enteroanastomosis by firing one 45 mm white load (Ethicon) or tan (Medtronic, formerly Covidien). The introductory opening was closed with a single row, running absorbable suture. Finally, the small intestine was divided with one 45 mm white load (Ethicon) or tan (Medtronic, formerly Covidien) between the gastro-entero-enteroanastomosis and the entero-enteroanastomosis in order to complete a bypass with an alimentary limb of 120 cm and a bileopancreatic limb of 60 cm[@R25]. The mesentery was not divided, and the omentum was only divided if indicated. A leak test with methylene blue was performed and the pouch inspected on both sides. The mesenteric defects under the entero-enteroanastomosis and at Peterson's space were closed with a running, non-absorbable suture or non-absorbable clips.

### Sleeve gastrectomy {#s2d2}

The greater curvature was dissected free starting 4--5 cm from the pylorus up to the angle of Hiss. The left crus was visualised and inspected for hiatal hernia. Small sliding hernias and wide hiatus were left in situ. The ventricle was then lifted and any adhesions in the lesser sac divided. A 35 Fr bougie was placed down to the pylorus guiding the creation of a tubular sleeve with linear staplers. The first two loads were always green (Ethicon) or purple (Covidien), while blue (Ethicon) or tan (Medtronic, formerly Covidien) loads were used for the rest of the ventricle. The last stapler was placed 5 mm laterally to the angle of Hiss. The staple line was then inspected and secured with clips for additional haemostasis, no oversewing or buttressing material was routinely used. A leak test was performed with 100 mL methylene blue. The specimen was retrieved from one of the trocar sites and visually examined for pathology, no routine histological assessment was performed.

### Concomitant care {#s2d3}

The two intervention groups receive identical concomitant care. Both groups completed a low-calorie diet (\<1200 kcal/day) in the 2 weeks preceding surgery, and, at all visits throughout the study, the patients are informed about the importance of lifestyle behaviour change, diet and physical activity. All patients receive advanced medical therapy defined as the implementation of current (2012) international guidelines to optimise management of hyperglycaemia, elevated blood pressure and dyslipidaemia.[@R26] Specific algorithms for antidiabetic treatment, blood pressure management, statin therapy, as well as management of reflux disease and vitamin and mineral supplementations, were implemented in order to achieve the recommended treatment targets (online [supplementary file 1](#SP1){ref-type="supplementary-material"}).
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Outcome measure {#s2e}
---------------

### Primary outcome measures {#s2e1}

-   Proportion of participants with complete remission of type 2 diabetes (HbA1c≤6.0% in the absence of glucose-lowering drug therapy),[@R29] 1 year after surgery.

-   The disposition index measured as a continuous variable,[@R30] 1 year after surgery.

### Secondary outcome measures {#s2e2}

Secondary outcome measures are listed in [box 1](#B1){ref-type="boxed-text"}. The summary measures for the two surgical groups include mean/median and proportions as appropriate. Outcome variables include changes from baseline, final values and time to events, and will be measured at baseline, 5 weeks, 16 weeks, 34 weeks, 1 year and annually for 4 more years (see [table 1](#T1){ref-type="table"}).Box 1Secondary outcome measuresGlucose homoeostasisHbA1cInsulin secretion and actionFasting and stimulated levels of glucose and insulinUse of antidiabetic medicationGastrointestinal hormone levelsGastric emptying rateBody weight and compositionBody weight, body mass index, waist circumference and hip circumferenceBody compositionObesity-related cardiovascular comorbiditiesResting systolic and diastolic blood pressureTwenty-four hours ambulatory blood pressureUse of blood pressure lowering drugsPulse wave velocityCholesterol and triglyceride levelsUse of lipid-lowering agentsObstructive sleep apnoea scoreMicroalbuminuriaGastrointestinal tract and liverGastro-oesophageal reflux disease and oesophageal motilityFatty liver diseaseGut microbiota and microbiomeSelf-reported gastrointestinal symptomsPhysical activityMeasured physical activitySelf-reported physical activityEnergy intake and eating behaviourFood frequencyFood toleranceEating patternsObesity specific well-beingHealth-related quality of lifeObesity-related symptomsPsychological distressHarmsSurgical and medical complicationsHypoglycaemic episodes and early dumpingVitamin and mineral deficienciesBone mineral density and metabolismLength of hospital stayReadmissions

###### 

Patient visit schedule

  -------------------------------------------------------------------------------------------------------------------------------------------------
  Time\                                         Screening   Baseline   Operation\   Follow-up period                                       
  (accepted variation)                                                 0                                                                   
  --------------------------------------------- ----------- ---------- ------------ ------------------ ------- ------- ------- ----------- --------
  **Visit**                                     **1**       **2**      **3**        **4**              **5**   **6**   **7**   **8--10**   **11**

  Demographic data                                          x                                                                              

  Comorbidities                                             x                                                                              

  Regular medication                                        x                       x                  x       x       x       x           x

  Clinical examination                                      x          x            x                  x       x       x       x           x

  Physician consultation                        x           x                       x                  x       x       x       x           x

  Inclusion and exclusion criteria              x                                                                                          

  Signed informed consent                       x                                                                                          

  Blood samples\*                               x           x          x            x                  x       x       x       x           x

  Urine samples\*                                           x                       x                                  x                   x

  Faecal sample\*                                           x                       x                                  x                   x

  Pulse wave velocity                                       x                       x                                  x                   x

  Bioelectrical impedance analysis                          x                       x                  x       x       x       x           x

  ECG                                                       x                                                          x                   x

  OGTT and FSIGT                                            x                       x                                  x                   x

  PROMs questionnaires (web)                                x                       x                                  x       x           x

  Food frequency questionnaire                              x                                                          x                   x

  DEXA                                                      x                                                          x                   x

  MRI                                                       x                       x                                  x                   x

  Upper endoscopy                                           x                                                          x                   x

  Manometry                                                 x                                                          x                   x

  pH measurement                                            x                                                          x                   x

  Twenty-four hours ambulatory blood pressure               x                       x                                  x                   x

  SenseWear                                                 x                       x                                  x                   x

  ApneaLink                                                 x                       x                                  x                   x

  Hypoglycaemia/dumping                                     x                       x                  x       x       x       x           x

  Adverse events                                                       x            x                  x       x       x       x           x
  -------------------------------------------------------------------------------------------------------------------------------------------------

\*See [table 2](#T2){ref-type="table"}.

DEXA, dual-energy X-ray absorptiometry; FSIGT, frequently sampled glucose tolerance test; OGTT, oral glucose tolerance test; PROMs, patient-reported outcome measures.

Participant timeline {#s2f}
--------------------

A total of 319 out of 1471 patients on the waiting list for bariatric surgery had type two diabetes. Among these, 248 patients fulfilled the inclusion criteria and were invited to participate in the study. Ninety patients declined participation and the remaining 158 patients gave informed consent and underwent the screening examination. A total of 30 patients did not meet the inclusion criteria at screening and three withdrew their consent. One hundred and twenty-five patients underwent baseline examination out of whom 16 were excluded due to abnormal gastrointestinal findings or other exclusion criteria, leaving 109 patients to be randomised and subsequently allocated to sleeve gastrectomy or gastric bypass. The first patient was included in January 2013 and the last patient was included in February 2018. Study flow chart and timeline are illustrated in [figures 1 and 2](#F1 F2){ref-type="fig"}, respectively.

![Flowchart.](bmjopen-2018-024573f01){#F1}

![Timeline.](bmjopen-2018-024573f02){#F2}

The Oseberg study includes several test and examinations very shortly after surgery when weight loss is expected to be low (5 weeks), after expected maximal weight loss (1 year) and during possible weight regain (one to 5 years). This comprehensive follow-up enables us to evaluate very early, medium and long-term effects of gastric bypass and sleeve gastrectomy with varying degrees of weight loss. Clinical examinations and tests with scheduled time points for assessment are listed in [table 1](#T1){ref-type="table"}, and a list of the blood, urine and faeces samples that have been and will be collected, including time points for collection, is presented in [table 2](#T2){ref-type="table"}. One-year follow-up will be completed in March 2019 and the end of the study period is in December 2023.

###### 

Method principles, sample matrix, units and analytical precision of laboratory measurements

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Analyte                                    Method principle   Sample matrix                            Unit      Precision\         Time point for collection\
                                                                                                                   (CV, analytical)   (visit number)\*
  ------------------------------------------ ------------------ ---------------------------------------- --------- ------------------ ----------------------------
  Ferritin                                   ECLIA              Serum                                    µg/L      7%                 1--11

  Iron                                       Photometry         Serum                                    µmol/L    4%                 1--11

  Transferrin                                Photometry         Serum                                                                 1--11

  Vitamin B12                                ECLIA              Serum                                    pmol/L    12%                1--11

  Folic acid                                 ECLIA              Serum                                    nmol/L    12%                1--11

  C reactive protein                         Photometry         Serum                                    mg/L      5%                 1--11

  Creatinine                                 Photometry         Serum                                    µmol/L    2.5%               1--11

  Sodium                                     ISE                Serum                                    mmol/L    1.0%               1--11

  Potassium                                  ISE                Serum                                    mmol/L    1.2%               1--11

  Calcium                                    Photometry         Serum                                    mmol/L    1.5%               1--11

  Magnesium                                  Photometry         Serum                                    mmol/L    3.0%               1--11

  Phosphate                                  Photometry         Serum                                    mmol/L    2.0%               1--11

  Albumin                                    Photometry         Serum\                                   g/L       3.0%               1--11\
                                                                Urine                                                                 2, 4, 7 and 11

  Total protein                              Photometry         Serum                                    g/L       2.5%               1--11

  Uric acid                                  Photometry         Serum                                    µmol/L    4.0%               1--11

  Glucose                                    Photometry         Serum/plasma                             mmol/L    2.0%               1--4, 7 and 11

  Alanine aminotransferase                   Photometry         Serum                                    U/L       5%                 1--11

  Aspartate transaminase                     Photometry         Serum                                    U/L       9.0%               1--11

  Alkaline phosphatase                       Photometry         Serum                                    U/L       3.0%               1--11

  Gamma-glutamyl transpeptidase              Photometry         Serum                                    U/L       3.0%               1--11

  Lactate dehydrogenase                      Photometry         Serum                                    U/L       5.5%               1--11

  Creatine kinase                            Photometry         Serum\                                   U/L       5.0%               1--11\
                                                                Urine                                                                 2, 4, 7 and 11

  Bilirubin                                  Photometry         Serum                                    µmol/L    5.0%               1--11

  Amylase                                    Photometry         Serum                                                                 1--11

  Total cholesterol                          Photometry         Serum                                    mmol/L    2.5%               1--11

  HDL cholesterol                            Photometry         Serum                                    mmol/L    3.0%               1--11

  LDL cholesterol                            Photometry         Serum                                    mmol/L    3.0%               1--11

  Triglycerides                              Photometry         Serum                                    mmol/L    3.0%               1--4, 7 and 11

  Thyroid-stimulating hormone                ECLIA              Serum                                    mIE/L     5.0%               1--11

  Unbound triiodothyronine                   ECLIA              Serum                                    pmol/L    5.0%               1--11

  Unbound thyroxine                          ECLIA              Serum                                    pmol/L    5%                 1--11

  Parathyroid hormone                        ECLIA              Plasma                                   pmol/L    6.0%               1--11

  25-OH-vitamin D                            ECLIA              Serum                                    nmol/L    6.5%               1--11

  Β-human chorionic gonadotropin†            ECLIA              Serum                                    IE/L      5.0%               1

  Paracetamol                                Photometry         Serum                                    µmol/L    3.0%               2, 4, 7 and 11

  HbA1c                                      HPLC               Blood                                    \%        1.4%               1--11

  Complete blood count                       Photometry\        Blood                                    g/dL\     1.0%--10.0%        1--11
                                             Impedance\                                                  %\                           
                                             Flow cytometry                                              cells/L                      

  Thiamin                                    HPLC               Serum                                    nmol/L    4.5%               2 and 4--11

  Bone alkaline phosphatase                  CLIA               Serum                                    U/L       9.5 U/L 10%\       2 and 4--11
                                                                                                                   45 U/L 13%         

  C-telopeptide of type I collagen           ECLIA              Serum                                    µg/L      0.12 µg/L 13%\     2 and 4--11
                                                                                                                   0.32 µg/L 8%       

  Procollagen type I N-terminal propeptide   ECLIA              Serum                                    µg/L      5%                 2 and 4--11

  Insulin                                    ECLIA              Serum                                    pmol/L    4%                 2, 4, 7 and 11

  C peptide                                  ECLIA              Serum                                    pmol/L    4%                 2, 4, 7 and 11

  Anti-GAD                                   IP                 Serum                                    ai        0.25 ai 25%\       1
                                                                                                                   1.45 ai 8%         

  Anti-IA2                                   IP                 Serum                                    ai        0.32 ai 18%\       1
                                                                                                                   1.66 ai 12%        

  Samples for storage                                           Serum, plasma, blood, urine and faeces                                1--4, 7 and 11
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Fasting blood samples visit 2, 4, 7 and 11.

†Women only.

ai, antibody index; CLIA, chemiluminescent immunoassay; CV, coefficient of variation; ECLIA, electro-CLIA; HPLC, high-performance liquid chromatography; IP, immunoprecipitation; ISE, ion selective electrode.

Sample size {#s2g}
-----------

This study has two primary endpoints and was powered thereafter. On the basis of previous research addressing glycaemic response of gastric bypass and sleeve gastrectomy in type 2 diabetic subjects[@R9] remission rates of 75% and 50%, respectively, were assumed.

Data on disposition index after sleeve gastrectomy derived from a frequently sampled intravenous glucose tolerance test (FSIGT) was not available before study start, and data from a study addressing β-cell function after gastric bypass and a low-calorie diet was, therefore, used for sample size determination.[@R35] Mean (SD) disposition index was 268 (232) after gastric bypass and 94 (92) after a low-calorie diet. On the basis of these figures mean (SD) disposition index after gastric bypass and sleeve gastrectomy was estimated to be 270 (160) and 180 (160) 1 year after surgery, respectively.

Given a 5% significance level and 80% power and an equal distribution to the two groups, a total study sample of 110 (remission) or 100 (disposition index) subjects was required to reveal a difference between groups. In order to accommodate possible dropouts (5% in previous study at our centre),[@R9] we planned to include 120 subjects in the study. Due to a higher than expected number of excluded patients after baseline examinations, the baseline study population was increased to 125.

Recruitment {#s2h}
-----------

The electronic medical records of all patients on the waiting list for bariatric surgery at the Morbid Obesity Centre were reviewed by one of the principal investigators (DH). Patients eligible for inclusion were contacted by phone (DH) and invited to an information meeting a few months prior to surgery. Patients who then approved participation signed the informed consent and underwent a screening procedure.

Allocation---sequence generation and concealment {#s2i}
------------------------------------------------

The allocation sequence was created by one of the bariatric surgeons (MS), not involved in the recruitment or follow-up of the patients, using a computerised random number generator ([randomization.com](randomization.com)) with a 1:1 allocation using blocks sizes of 10. Opaque envelopes were sequentially numbered, and a note with the procedure to be conducted, according to the randomisation list, was placed inside the envelope. The envelopes were then sealed and stored inside locked cabinets. Only authorised staff members, including the person who uploaded the sequence to the web-based randomisation service, have access to the allocation sequence. The investigators responsible for patient recruitment, or clinicians who are in contact with the patients, do not have access to the allocation sequence. The allocation for each specific patient was revealed, to the surgical staff only, in the operating room on the day of surgery. Afterwards, the envelope with the randomisation code was resealed and stored in the coordinating office in locked cabinets. The surgical staff were not involved with patient follow-up after the surgical procedure.

Blinding {#s2j}
--------

The triple blinding refers to blinding of patients, study personnel engaged in all visits until the 1-year follow-up and the person(s) analysing the primary outcomes. Surgical incisions from the two procedures are identical, and postsurgical follow-up and treatment are similar for all patients. The randomisation code will remain concealed until data for the primary outcomes have been collected at 1 year. The research physician is then be responsible for including the actual type of surgery in the patient's electronic medical record and for informing the patient. The code will only be broken during the first year if there is an unexpected complication or a need for reoperation. A list linking name and study identification number with study procedure is available at the study office and in the emergency department---all patients are aware of this. The research physician must report all code breaks (with reason) in the case report form.

Data collection methods {#s2k}
-----------------------

### Primary outcomes {#s2k1}

#### Remission of type 2 diabetes {#s2k1a}

Whole blood HbA1c will be analysed on a Tosoh high-performance liquid chromatography G8 analyser (Tosoh Corporation, Tokyo, Japan) with reagents from the supplier. The analytical variation (CV~at~) is estimated to be 1.4%.

#### Disposition index {#s2k1b}

The disposition index, a valid surrogate measure of β-cell function, is the product of insulin sensitivity and the insulin secretory response to a glucose challenge (insulin sensitivity index (S~i~)×acute insulin response (AIRg)). S~i~ and AIRg will be estimated with the Bergman minimal model (MINMOD Millennium software),[@R36] which uses glucose and insulin data obtained from a FSIGT.[@R30] The laboratory analyses used for quantifying insulin and glucose are shown in [table 2](#T2){ref-type="table"}.

Execution of the FSIGT: The patients are asked to avoid vigorous physical activity 1 week prior to the test. The patients must also terminate treatment with long-acting GLP-1 analogues and other antidiabetic medications 6 weeks and 48 hours prior to the test, respectively. The participants are not allowed to drink (up to 2 dL of water is allowed), eat or smoke 8 hours prior to the test. Other morning medications are delayed until after the tests. A cannula is inserted into a cubital vein and the cannulated arm wrapped in a heat pad throughout the experiment for the collection of arterialised blood samples. A cannula is then inserted in the contralateral cubital vein for glucose and insulin infusion. Due to patient safety, the upper limit of fasting blood glucose prior to FSIGT was set to \<20 mmol/L. Blood samples are drawn two times before (−5 and 0 min) and after 2, 4, 8, 19, 22, 30, 40, 50, 70, 90 and 180 min after the intravenous glucose load (300 mg/kg body weight). After 20 min, a bolus of insulin is administrated (0.03 U/kg body weight). Blood will, at all time points, be collected in (1) one tube, which will be centrifuged after 30 min, serum will then be put on ice and stored at −80°C until the analysis of insulin and (2) one tube containing lithium heparin, which will be centrifuged immediately before the analysis of plasma glucose the same day. See [table 2](#T2){ref-type="table"} for method principles, sample matrix, units and analytical precision of glucose and insulin analysis.

### Secondary outcomes {#s2k2}

See online [supplementary file 2](#SP2){ref-type="supplementary-material"} for data collection methods of the secondary outcomes. Routine laboratory measurements will be performed at the Central Laboratory, Vestfold Hospital Trust. The laboratory is accredited according to NS-EN ISO 15189 and serves as the main analytical facility in the hospital. Complete blood count will be analysed on Sysmex XN-9000 with reagents from the supplier (Sysmex Corporation, Kobe, Japan). General clinical chemistry and immunochemistry were analysed on Cobas 8000 with modules ISE, c702 and e801 (Roche Diagnostics, Basel, Switzerland). Thiamin, bone markers, insulin, C peptide, Anti-GAD and Anti-IA2 will be analysed at Oslo University Hospital using established methods. A complete list of method principles, sample matrix, units and analytical precision are given in [table 2](#T2){ref-type="table"}.
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### Retention {#s2k3}

Once a participant is included, every reasonable effort is made to prevent attrition through the entire study period. In addition to the planned visits, all participants have, during the last 2 years, received two letters in connection with milestones and holidays. Distribution of letters will continue throughout the entire study period. Loss to follow-up is estimated to be 5% or less.[@R9]

Data management {#s2l}
---------------

Authorised individuals enter all data electronically and into the original study forms. Data integrity is enforced through referential data rules, valid values and range checks. Data are stored on a secure and password-protected electronic research server. The original study forms are stored in locked cabinets at the study location. Participant files will be kept in storage for a period of at least 10 years after completion of the study.

Statistical methods {#s2m}
-------------------

Data will be analysed according to both the intervention into which patients were randomised (intention-to-treat analysis) and per-protocol. Descriptive data will be presented as mean (SD), median (range) or number (%). Between-group comparisons will be analysed using independent samples t-test, repeated measures analysis of variance, mixed model analysis and Mann-Whitney U test for continuous variables and χ^2^, Fisher's exact test and binary logistic regressions for repeated measures for categorical variables as appropriate. Regression analysis will be used for the exploration of the independent effects of weight reduction and other variables on primary and secondary outcomes.

Data monitoring {#s2n}
---------------

The steering committee consists of a team of healthcare professionals, researchers and a patient representative. Members of the steering committee meet every sixth month and safeguard the interests of trial participants and monitor the overall conduct of the clinical trial. Adverse events are consecutively reported. Harms are specified as secondary outcomes in the section secondary outcome measures.

Ethics and dissemination {#s3}
========================

Research ethics approval {#s3a}
------------------------

The study protocol was registered in an international trial register (ClinicalTrials.gov) on 03 December 2012. See online [supplementary file 3](#SP3){ref-type="supplementary-material"} for a brief structured summary of the study (WHO Trial Registration Data Set). The study is conducted according to the Declaration of Helsinki.
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Protocol amendments {#s3b}
-------------------

Significant amendments to the protocol have been/will only be made after ethical approval by the regional ethics committee. For previous amendments, see online [supplementary file 4](#SP4){ref-type="supplementary-material"}.
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Informed consent {#s3c}
----------------

After a thorough evaluation of the existing literature prior to the approval of the study protocol in 2012, and after balancing clinical effects and side-effects, no evidence was found suggesting gastric bypass or sleeve gastrectomy to be a better choice for patients with type 2 diabetes. Research assistants and patients were informed about the lack of evidence before the start of the study, and one of the principal investigators (DH) obtained informed consents in face-to-face meetings.

Ancillary studies {#s3d}
-----------------

Additional biological samples (urine, blood, serum, plasma and faeces) will be obtained and stored for use in future studies. Information about storage and analyses of biological samples was covered in the original informed consent for the Oseberg study.

Confidentiality {#s3e}
---------------

All participants are given a study ID, which will be used during data analyses. The key linking name and study ID is kept on a password-protected server. Participants' study information will not be released outside of the study without the written permission of the participant.

Access to data {#s3f}
--------------

Selected study personnel, authorised to enter data electronically, and investigators within the Oseberg study have access to the final trial data set. Researchers within the Oseberg study must seek approval from the principal investigators prior to initiating data analyses.

Ancillary and post-trial care {#s3g}
-----------------------------

The patients will receive post-trial follow-up according to national guidelines.[@R37]

Dissemination {#s3h}
-------------

The protocol and the results of the study (primary and secondary endpoints at 1 and 5 years) will be published in international peer-reviewed journals in accordance with the ICMJE criteria for authorship (<http://www.icmje.org/ethical_1author.html>). The executive and steering committees will actively contribute to the involvement and inclusion of authors and the order of authorships in the planning of publications. The results will also be disseminated through networks of scientists, conferences, professionals, and policymakers and commissioners of weight management.
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